Remote-Controlled Gene Editing: Integrating Electrogenetics with CRISPR for Precision Therapy

Remote-Controlled Gene Editing: Integrating Electrogenetics with CRISPR for Precision Therapy | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL This is a preprint and has not been peer reviewed. Data may be preliminary. 18 June 2025 V1 Latest version Share on Remote-Controlled Gene Editing: Integrating Electrogenetics with CRISPR for Precision Therapy Author : Mohammad Mahboob Kanafi 0000-0003-3335-9290 [email protected] Authors Info & Affiliations https://doi.org/10.22541/au.175026437.79607454/v1 518 views 190 downloads Contents Abstract Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract The CRISPR-Cas system has revolutionized gene editing and transcriptional regulation, yet its therapeutic and synthetic potential is limited by a lack of spatiotemporal control. Electrogenetics using electrical signals to modulate gene expression offers a dynamic, reversible, and non-invasive solution to this challenge. This review explores the integration of electrogenetic technologies with CRISPR platforms to enable externally controllable gene regulation. We discuss key molecular mechanisms, including ROS and calcium-mediated pathways, and highlight strategies for engineering electrically responsive CRISPR circuits using inducible promoters and modular components. Bioelectronic interfaces such as microelectrode arrays, conductive scaffolds, and implantable devices are reviewed for their roles in precise electrical stimulation. Applications in precision medicine, regenerative therapy, data storage, and environmental biosensing are examined, along with comparisons to other control modalities such as optogenetics and chemical inducers. We assess the benefits of electrogenetics in terms of depth of tissue penetration, programmability, and clinical integration. Finally, the review outlines challenges in biocompatibility and signal tuning, and explores future directions combining electrogenetics with artificial intelligence and cyber-physical systems. Together, these advances position electrogenetic-CRISPR systems as a foundation for intelligent, patient-specific gene therapies and programmable biointerfaces. Remote-Controlled Gene Editing: Integrating Electrogenetics with CRISPR for Precision Therapy Mohammad Mahboob Kanafi Human Genetic Research Centre, Baghyatollah University of Medical Science, Tehran, Iran. Corresponding author: Mohammad Mahmood Kanafi (email: [email protected] ) Tel: +989120518031 The CRISPR-Cas system has revolutionized gene editing and transcriptional regulation, yet its therapeutic and synthetic potential is limited by a lack of spatiotemporal control. Electrogenetics using electrical signals to modulate gene expression offers a dynamic, reversible, and non-invasive solution to this challenge. This review explores the integration of electrogenetic technologies with CRISPR platforms to enable externally controllable gene regulation. We discuss key molecular mechanisms, including ROS and calcium-mediated pathways, and highlight strategies for engineering electrically responsive CRISPR circuits using inducible promoters and modular components. Bioelectronic interfaces such as microelectrode arrays, conductive scaffolds, and implantable devices are reviewed for their roles in precise electrical stimulation. Applications in precision medicine, regenerative therapy, data storage, and environmental biosensing are examined, along with comparisons to other control modalities such as optogenetics and chemical inducers. We assess the benefits of electrogenetics in terms of depth of tissue penetration, programmability, and clinical integration. Finally, the review outlines challenges in biocompatibility and signal tuning, and explores future directions combining electrogenetics with artificial intelligence and cyber-physical systems. Together, these advances position electrogenetic-CRISPR systems as a foundation for intelligent, patient-specific gene therapies and programmable biointerfaces. not-yet-known not-yet-known not-yet-known unknown Introduction Recent advances in gene editing technologies, particularly the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system, have revolutionized our ability to manipulate the genome with unprecedented precision. CRISPR-based systems, including CRISPR/Cas9 and CRISPR interference/activation (CRISPRi/a), offer powerful platforms for gene editing and transcriptional regulation across diverse biological contexts. Despite these advantages, one of the major challenges limiting their therapeutic and synthetic applications is the lack of precise spatiotemporal control over their activity [1]. To address this challenge, researchers have developed inducible systems that respond to external stimuli such as light (optogenetics), chemicals, temperature, or electromagnetic fields. Among these, electrogenetics An error in the conversion from LaTeX to XML has occurred here. the use of electrical stimuli to control gene expression An error in the conversion from LaTeX to XML has occurred here. has emerged as a particularly promising approach. It enables reversible, non-invasive, and programmable modulation of cellular behavior with high temporal resolution and tissue penetrance [2]. The convergence of electrogenetics with CRISPR systems represents a transformative step in the development of next-generation bioelectronic interfaces and programmable therapeutic tools. By integrating electric signals with gene-editing circuits, it becomes possible to remotely and dynamically regulate gene function in living cells and organisms. Furthermore, this synergy opens up new frontiers in areas such as smart gene therapy, bioelectronic implants, and molecular data storage, where information can be written into the genome in response to electrical inputs [3]. In this review, we comprehensively explore the principles, mechanisms, and applications of electrogenetic control of CRISPR systems. We compare this modality with other stimuli-responsive systems, examine emerging technologies enabling this interface, discuss therapeutic and synthetic biology applications, and highlight current challenges and future opportunities in this rapidly evolving field [4] The CRISPR Toolbox: Gene Editing and Transcriptional Modulation The CRISPR-Cas system, originally discovered as a component of bacterial adaptive immunity, has rapidly become the cornerstone of modern gene editing and programmable gene regulation. Its core mechanism \RL targeted DNA recognition via a guide RNA and site-specific cleavage by a Cas nuclease \RL offers an unparalleled level of specificity and flexibility. Among the various implementations of CRISPR technology, the CRISPR/Cas9 system has emerged as the most widely adopted due to its simplicity, modularity, and broad applicability across species [5]. In its native editing form, CRISPR/Cas9 induces double-strand breaks (DSBs) at predetermined genomic loci, which are subsequently repaired through endogenous cellular mechanisms. The non-homologous end joining (NHEJ) pathway, often the dominant repair route, can introduce small insertions or deletions that disrupt gene function. Alternatively, when a homologous repair template is present, the homology-directed repair (HDR) pathway enables precise genetic modifications. Beyond Cas9, other endonucleases such as Cas12a and Cas13 have expanded the CRISPR toolkit by providing options for single-strand cutting, RNA targeting, and altered PAM requirements [6]. Importantly, the CRISPR platform has evolved beyond its editing capabilities into a robust framework for transcriptional regulation. By inactivating the catalytic domains of Cas9 through point mutations \RL yielding so-called ”dead” Cas9 (dCas9) \RL researchers have engineered DNA-binding proteins that retain sequence specificity without nuclease activity. When fused to effector domains such as transcriptional activators (e.g., VP64, p300) or repressors (e.g., KRAB), dCas9 becomes a programmable regulator of gene expression, capable of upregulating or silencing genes without altering genomic sequence. This has opened the door to applications in cell reprogramming, synthetic gene circuits, and epigenetic modulation [7]. Despite the technological maturity of CRISPR systems, a major limitation remains: the lack of intrinsic spatiotemporal control. In most implementations, CRISPR effectors are expressed constitutively, which can lead to off-target effects, unintended cellular responses, and a lack of precision in dynamic or tissue-specific contexts. Addressing this gap has spurred the development of inducible CRISPR systems that can be externally controlled in both time and space. To that end, a variety of stimuli-responsive systems have been devised, enabling CRISPR regulation through chemical, optical, thermal, or physical triggers. Chemical inducers like doxycycline and rapamycin allow conditional expression of CRISPR components, while optogenetic systems enable light-dependent activation using photoreceptor fusion proteins. Thermogenetic approaches utilize heat-sensitive promoters to restrict activity to thermal windows. More recently, electrical stimuli have gained traction as a highly promising control modality. Unlike light or chemical triggers, electrical signals can penetrate deep tissues, be precisely modulated in real-time, and be readily integrated with implantable or wearable bioelectronic devices. These features make electrical control particularly attractive for therapeutic applications, especially in settings where minimally invasive, programmable, and on-demand regulation of gene activity is critical [8]. In this context, the intersection of electrogenetics with CRISPR technology holds the potential to overcome current limitations and to establish a new paradigm of gene circuit control \RL one that is both biologically precise and electronically programmable\RL. Fundamentals of Electrogenetics Electrogenetics is an emerging interdisciplinary field that seeks to control gene expression in living systems using externally applied electrical signals. Rooted in the convergence of synthetic biology, bioengineering, and electrophysiology, electrogenetics offers a novel approach to modulate cellular behavior with high spatial and temporal precision. Unlike traditional gene control methods that rely on chemical or optical cues, electrical signals provide a unique modality that is both deeply penetrant and highly programmable, enabling remote, non-invasive control over biological function [9]. The principle underlying electrogenetics lies in the ability of cells muscle fibers \RL to respond to changes in electric potential. These responses are mediated by a variety of endogenous components, including voltage-gated ion channels, electrochemical gradients, and redox-sensitive transcription factors. By leveraging these native mechanisms or introducing synthetic, electrically responsive gene circuits, researchers can trigger specific cellular outcomes such as transcriptional activation, signal transduction, or metabolic switching [10]. At the molecular level, one of the key interfaces for electrogenetic control involves the generation of reactive oxygen species (ROS) as a byproduct of electrical stimulation. ROS, while often associated with oxidative stress, can serve as secondary messengers that activate redox-sensitive promoters such as EGR1 and HSP70. These promoters can be engineered to drive the expression of genes of interest in response to electrical cues. Additionally, ion channel-modulated calcium influx can activate intracellular signaling cascades that converge on transcriptional machinery, offering another layer of control [11,12]. To translate these biological phenomena into practical tools, electrogenetics relies on advances in bioelectronic hardware. Microelectrode arrays (MEAs), conductive polymer scaffolds, wireless neurostimulators, and nanowire-based interfaces are among the many platforms designed to deliver precise electrical inputs to cells or tissues. These devices vary in their spatial resolution, depth of penetration, and biocompatibility, but all aim to achieve the same goal: delivering safe and effective stimulation to modulate gene function in real time [13,14]. In synthetic systems, electrogenetic control circuits have been constructed by combining inducible promoters with synthetic transcription factors, allowing electric pulses to gate gene expression on demand. Recent studies have demonstrated that such systems can be used to regulate therapeutic transgenes, toggle genetic switches, or record environmental signals into DNA. These findings pave the way for the development of bioelectronic devices that not only read biological signals but also write genetic responses in living cells [15]. Importantly, electrogenetics offers several advantages over other stimulation modalities. Unlike light, electrical signals are not limited by scattering or absorption in biological tissue and can thus reach deep anatomical sites. Compared to chemical inducers, electrical stimuli can be applied with higher temporal resolution and without introducing exogenous molecules that may perturb cellular homeostasis. Moreover, electrical stimulation is inherently compatible with implantable medical devices, suggesting a seamless path toward clinical translation [16]. Nonetheless, challenges remain. Electrical stimulation must be carefully calibrated to avoid cellular damage, and the integration of electronic components into biological systems necessitates rigorous biocompatibility and long-term stability assessments. Furthermore, the diversity of cellular responses to electrical inputs demands careful design of electrogenetic circuits to ensure robustness and specificity. As the field continues to evolve, electrogenetics holds the promise of becoming a foundational technology for programmable biology. Its integration with gene-editing platforms like CRISPR will enable next-generation therapies, biointerfaces, and synthetic systems capable of responding dynamically to electrical commands \RL ushering in a new era of electronically guided genetic control\RL. not-yet-known not-yet-known not-yet-known unknown Engineering CRISPR Systems for Electrical Responsiveness The convergence of CRISPR-based gene regulation with electrogenetic stimulation represents a promising strategy for achieving precise, dynamic, and reversible control over genetic activity. To effectively integrate electrical inputs into CRISPR circuits, it is essential to develop systems in which the activity of CRISPR effectors An error in the conversion from LaTeX to XML has occurred here. such as Cas nucleases or transcriptional regulators An error in the conversion from LaTeX to XML has occurred here. can be modulated in response to electrical signals. This requires the careful engineering of gene circuits that interface with cellular pathways sensitive to electrochemical perturbations [17]. One of the most widely used approaches to achieve electrical control over CRISPR function involves coupling gene expression to electrically responsive promoters. Promoters such as EGR1, c-fos, and HSP70, which are up-regulated by oxidative or electrophysiological stress, have been shown to respond to extracellular electrical stimulation through the generation of reactive oxygen species (ROS) or calcium-mediated signaling. By placing Cas9, dCas9, or CRISPR-associated transcriptional effectors under the control of these promoters, their expression can be selectively induced when an electrical pulse is applied (Figure. 1) [18]. A complementary strategy involves the design of modular synthetic gene circuits that convert bioelectronic inputs into transcriptional responses. For instance, engineered transcription factors can be placed under the control of ROS-sensitive pathways or calcium-inducible domains. These transcription factors, in turn, can regulate CRISPR components via logic gates or feedback mechanisms. In this manner, electrical stimulation serves as the trigger for the assembly or activation of the CRISPR machinery [19]. In addition to transcriptional regulation, post-translational control mechanisms can be incorporated to fine-tune CRISPR activity. For example, Cas proteins can be fused with destabilization domains or protein switches that undergo conformational changes in response to electrically induced signaling molecules. This enables control at the protein level An error in the conversion from LaTeX to XML has occurred here. activating or inactivating the CRISPR system without altering transcriptional output [20]. Another innovative avenue involves split-Cas systems, in which the functional Cas9 protein is divided into two inactive fragments that can reconstitute only upon external stimulation. In an electrogenetic context, each fragment can be expressed under separate electrically responsive promoters, or their dimerization can be promoted via ROS- or voltage-sensitive linkers. This modularity enhances biosafety by preventing unintended activation in the absence of electrical input [21]. To facilitate the translation of these designs into living systems, researchers have explored the use of bioelectronic interfaces such as electrode-integrated tissue scaffolds and wireless neuro An error in the conversion from LaTeX to XML has occurred here. -stimulators. These platforms allow for the real-time delivery of programmable electrical stimuli to engineered cells or tissues, enabling the dynamic regulation of CRISPR circuits in vitro and in vivo. Importantly, the stimulation parameters An error in the conversion from LaTeX to XML has occurred here. such as voltage amplitude, frequency, and pulse duration An error in the conversion from LaTeX to XML has occurred here. can be precisely tuned to modulate the strength and timing of CRISPR activation, offering a high degree of control over gene expression profiles [22]. Despite significant progress, the development of electrogenetic-CRISPR systems remains an ongoing challenge. Electrical inputs can activate diverse intracellular pathways, and achieving specificity requires careful circuit design to minimize crosstalk and off-target effects. Moreover, the robustness of these systems under physiological conditions must be validated across different cell types and tissue environments [23]. Nevertheless, the programmable nature of CRISPR combined with the on-demand control enabled by electrical stimulation offers an attractive paradigm for next-generation gene regulation. As synthetic biology tools continue to evolve, it is anticipated that electrogenetically controlled CRISPR systems will become increasingly sophisticated, forming the basis for closed-loop bioelectronic therapies, responsive gene implants, and programmable living devices [24] Platforms and Interfaces for Electrogenetic-CRISPR Systems The successful implementation of electrogenetically controlled CRISPR systems hinges not only on genetic circuit design, but also on the development of bioelectronic interfaces capable of delivering controlled electrical stimuli to living cells in a safe, localized, and tunable manner. These platforms serve as the physical bridge between electronic inputs and biological responses, enabling real-time actuation of gene expression and gene editing in diverse contexts, from cultured cells to in vivo systems [25]. One of the foundational technologies in this domain is the microelectrode array (MEA) \RL a patterned grid of conductive elements that can deliver precise electrical stimulation to adherent cells or tissues. MEAs allow for high-resolution spatial targeting of electrical inputs, making them particularly useful for investigating the dose- and location-dependent effects of stimulation on CRISPR activation. Their use has been demonstrated in both neural and non-neural cell types, and ongoing innovations in electrode miniaturization and surface chemistry have significantly improved their compatibility with soft biological tissues [26]. Beyond 2D platforms, the integration of conductive biomaterials into three-dimensional tissue scaffolds has opened new avenues for electrogenetic control in organoids and engineered tissues. Conductive polymers such as polypyrrole (PPy), PEDOT:PSS, and graphene-based composites have been used to fabricate biocompatible scaffolds that can deliver uniform or patterned electric fields throughout a cellular construct. These platforms support not only electrical stimulation but also cell growth, differentiation, and structural organization, thereby enabling spatiotemporally precise regulation of CRISPR circuits in complex biological models [27]. The advent of wireless and implantable bioelectronic devices has further expanded the potential of electrogenetic-CRISPR interfaces in vivo. Flexible, stretchable electronics capable of conforming to soft tissues can be implanted subcutaneously or intracranially to deliver programmable pulses with minimal invasiveness. These devices can be powered externally via radiofrequency (RF), inductive coupling, or even photovoltaic stimulation, eliminating the need for tethered connections. Such systems have been used in animal models to modulate neural activity, cardiac function, and more recently, gene expression \RL demonstrating the feasibility of integrating programmable CRISPR responses into wearable or implantable therapeutic platforms [28]. Wireless neurostimulators and closed-loop bioelectronic systems are particularly promising for precision medicine applications. By combining real-time biosensing with on-demand CRISPR activation, these systems enable autonomous therapeutic intervention based on detected physiological states. For example, a glucose sensor could trigger insulin gene expression via an electrogenetic-CRISPR circuit only when blood sugar exceeds a defined threshold. This dynamic responsiveness holds significant promise for treating chronic conditions such as diabetes, epilepsy, and inflammatory disorders [29]. In parallel, efforts are underway to optimize the delivery of CRISPR components \RL including plasmid DNA, mRNA, and ribonucleoprotein (RNP) complexes \RL into electrogenetically controlled systems. Electroporation remains a viable strategy for transient transfection, especially in conjunction with inducible promoters activated by secondary electrical pulses. However, stable delivery and long-term expression in vivo require refined vectors and integration with electrical triggering elements [30]. Despite these advances, several engineering challenges persist. The design of electrodes and conductive materials must balance electrical performance with cytocompatibility, avoiding electrochemical byproducts or thermal damage. Electrical parameters such as voltage, pulse frequency, and duration must be precisely calibrated for each tissue type to ensure efficacy without toxicity. Moreover, ensuring long-term stability of implanted systems in the dynamic biological environment remains an area of active research [31]. As the field matures, the co-development of biological circuits and physical platforms will be essential. The seamless integration of gene-editing machinery with next-generation bioelectronics may ultimately enable closed-loop, intelligent systems capable of sensing, computing, and actuating genetic responses in real time \RL ushering in a new class of responsive, programmable biological therapies [32] Applications of Electrogenetic-CRISPR Systems (Figure. 2) The integration of electrogenetics with CRISPR technology offers a transformative platform for controlling gene function in a wide array of biological and therapeutic contexts. By enabling non-invasive, reversible, and temporally precise activation of CRISPR systems, this approach expands the scope of gene modulation far beyond what is achievable with static or constitutively active systems. Here, we outline key application domains where electrogenetic-CRISPR systems hold substantial promise. Precision Medicine and Targeted Gene Therapy Electrogenetically controlled CRISPR platforms offer an unprecedented level of control in therapeutic settings, enabling localized and time-resolved activation of gene-editing tools. In oncology, for instance, the ability to activate tumor-suppressor genes or silence oncogenes selectively at the tumor site via implanted or wearable stimulators could minimize systemic off-target effects and enhance therapeutic specificity [33]. Similarly, in inherited disorders, electrogenetic control allows for episodic activation of therapeutic genes only when clinically necessary, reducing the risks associated with continuous transgene expression [34]. Neurological applications are particularly compelling, given the long-standing use of electrical stimulation in neuromodulation. CRISPR systems engineered to respond to electric pulses could be used to upregulate neuroprotective genes or suppress excitotoxic pathways in conditions such as Parkinson’s disease, epilepsy, or chronic pain [35]. Such systems may function in conjunction with existing brain-computer interfaces, offering closed-loop therapeutic modulation of the central nervous system [36]. Regenerative Medicine and Tissue Engineering Tissue regeneration relies on tightly regulated patterns of gene expression that govern cell proliferation, differentiation, and matrix remodeling. Electrogenetic-CRISPR circuits offer a means to recapitulate these dynamic gene expression profiles in engineered tissues and organoids [37]. By embedding conductive scaffolds into 3D cellular constructs, researchers can modulate lineage-specific transcription factors in situ, thereby guiding stem cell fate decisions with electrical inputs [38]. Moreover, periodic stimulation can be used to mimic endogenous biophysical cues present during wound healing or morphogenesis, enhancing the fidelity of regenerative processes. The non-invasive nature of electrical stimulation makes it especially attractive for integration into implantable constructs designed for in vivo tissue repair [39]. Programmable Cellular Therapeutics Cell-based therapies are increasingly being engineered to act as living devices that sense and respond to their microenvironment. Electrogenetically regulated CRISPR systems enable the construction of cellular therapeutics with conditional logic \RL turning on gene expression programs only when electrically prompted [40]. For example, engineered immune cells could be activated to secrete cytokines or kill cancer cells in response to targeted stimulation, improving both safety and efficacy by avoiding systemic immune activation [41]. These capabilities align closely with the goals of synthetic biology, where the design of cellular logic gates and memory circuits can be enhanced by the inclusion of an electrical input channel. As programmable cell therapies move toward clinical adoption, the ability to remotely modulate their function will become increasingly desirable. Biological Memory and Data Storage A novel and rapidly evolving application of electrogenetic-CRISPR systems lies in the field of molecular data storage and cellular event logging. CRISPR has already been demonstrated as a tool for encoding information into DNA sequences \RL whether in the form of binary data, environmental exposures, or lineage-tracking barcodes [34]. By linking CRISPR activity to electrical stimuli, researchers can construct living memory devices that record the timing, frequency, or intensity of electrical events as specific genetic changes [35]. Such systems could function as intracellular “black boxes,” recording episodes of neural firing, muscle activation, or even artificial control signals for retrospective analysis. In more advanced constructs, electrical encoding of digital data into genomic DNA may offer a biocompatible, high-density medium for archival storage (Figure. 3) [36]. Environmental Biosensing and Biocontainment Finally, electrogenetically driven CRISPR systems offer utility in environmental applications such as biosensing, where engineered microbes or cells can be deployed to detect contaminants or specific conditions and report them through controlled gene expression [37]. Integration with remote electrical stimulation allows for the activation of detection circuits only when required, thereby conserving cellular energy and minimizing unintended responses [38]. Moreover, this approach offers a potential mechanism for biocontainment, wherein engineered organisms can only function in the presence of a specific electrical signature \RL acting as a “kill switch” or an activation gate that prevents escape or unintended spread [39]. Across these diverse applications, electrogenetic-CRISPR systems provide a versatile framework for dynamic, programmable biological control. Whether in the clinic, the lab, or the environment, the ability to interface electronic signals with genetic function opens new paradigms in both fundamental research and applied biotechnology\RL. not-yet-known not-yet-known not-yet-known unknown Comparative Evaluation with Other Control Modalities To enable precise and dynamic gene control, various external stimuli have been employed to regulate CRISPR systems. These include chemical inducers, light (optogenetics), temperature (thermogenetics), and electric fields (electrogenetics). Each approach presents unique advantages and limitations based on how they interact with biological tissues and how easily they can be controlled or integrated into devices. Chemical inducers offer reliable gene activation but suffer from slow responses, systemic diffusion, and potential toxicity [42]. Optogenetics allows for rapid and localized control with light but is limited by poor tissue penetration and the need for specialized optical setups [43]. Thermal and magnetic controls provide non-contact stimulation but require complex hardware and can risk thermal damage [44]. In contrast, electrogenetics combines deep tissue accessibility with millisecond-level precision, compatibility with implantable devices, and no reliance on drugs or light. It stands out as a clinically promising modality, especially when integrated with programmable CRISPR systems for responsive and reversible gene control [45] Temporal Resolution Minutes–hours Milliseconds–seconds Seconds–minutes Milliseconds Spatial Resolution Systemic High (superficial) Moderate Moderate to high (deep) Tissue Penetration High Low Variable High Reversibility Moderate High Moderate High External Hardware Minimal Requires optics Requires heating/magnets Electrodes/electronics Clinical Compatibility Variable Limited Emerging High Table No. 1; this table presents a comparative summary of key characteristics across four major control modalities used for inducible CRISPR regulation: chemical inducers, optogenetics, thermogenetics, and electrogenetics. Evaluation criteria include temporal and spatial resolution, tissue penetration, reversibility of control, hardware requirements, and compatibility with clinical use. Electrogenetics demonstrates notable advantages in deep tissue penetration, rapid reversibility, and seamless integration with electronic hardware, making it a strong candidate for next-generation therapeutic applications. Integration with AI and Cyber-Physical Systems As biological systems become increasingly programmable, their integration with computational frameworks \RL particularly artificial intelligence (AI) and cyber-physical systems (CPS) \RL is emerging as a key frontier in synthetic biology and precision medicine. The electrogenetic control of CRISPR systems presents a uniquely compatible interface for such integration, due to its direct responsiveness to electronic signals and real-time tunability. This synergy enables the construction of intelligent, closed-loop systems in which biological behavior is dynamically regulated based on sensed physiological or environmental states [46]. Closed-Loop Control and Feedback Systems In traditional gene therapy or cellular engineering, genetic programs are predesigned and statically executed, regardless of changing conditions. However, by incorporating real-time biosensors and electrical feedback systems, electrogenetic-CRISPR circuits can be activated conditionally \RL responding to specific biochemical signals such as glucose levels, pH shifts, or inflammatory markers. Electrical stimulators can then actuate gene expression precisely when needed, reducing off-target effects and improving therapeutic outcomes [47]. Such closed-loop architectures have been demonstrated in animal models, where sensors trigger localized electrical stimulation that activates gene expression or silences specific pathways via CRISPR interference. These systems resemble bioelectronic reflex arcs, where sensing, processing, and actuation are fully integrated [48]. Role of Artificial Intelligence in Electrogenetic-CRISPR Control Artificial intelligence, especially machine learning (ML), enhances the adaptability and precision of bioelectronic systems. In the context of CRISPR-electrogenetics, AI algorithms can: • Analyze real-time biosensor data to predict optimal stimulation patterns\RL. • Model the nonlinear dynamics of gene expression responses to varying electrical inputs\RL. • Personalize stimulation protocols for individual patients based on biological variability\RL. • Detect and correct for drift, noise, or unexpected cellular responses\RL. For instance, deep reinforcement learning can be used to train a system to optimize CRISPR activation while minimizing cellular stress or immune response. Over time, such systems can become self-tuning, adapting their behavior without manual reprogramming [49]. Bio-Cyber Interfaces and Internet of Bio-Nano Things The coupling of electrogenetic CRISPR platforms with wireless communication and cloud-based control enables their integration into broader cyber-physical ecosystems. This concept, sometimes referred to as the Internet of Bio-Nano Things (IoBNT), envisions a network of embedded bio-devices capable of communicating with each other and with digital infrastructure [50]. Challenges, Risks, and Future Opportunities Despite the promising convergence of electrogenetics and CRISPR technology, the path toward widespread application is paved with substantial challenges that must be addressed through interdisciplinary research and careful system design. These challenges span the biological, technical, and translational domains, and overcoming them is essential for the safe and effective deployment of these hybrid bioelectronic systems. not-yet-known not-yet-known not-yet-known unknown Biological and Technical Challenges At the cellular level, the response to electrical stimulation is highly context-dependent and varies significantly across cell types, tissue architectures, and physiological states. Ensuring predictable and reproducible CRISPR activation via electrical inputs requires a deep understanding of cellular electrophysiology and stress response pathways [2]. Moreover, electrogenetic control relies heavily on reactive oxygen species (ROS) or calcium signaling, which, if not tightly regulated, can lead to off-target effects, cytotoxicity, or long-term cellular dysfunction [11]. From an engineering standpoint, electrode biocompatibility and stability remain critical issues. Chronic implantation of stimulating devices can provoke immune responses or tissue encapsulation, which in turn alters the electrical interface and reduces effectiveness over time [31]. Furthermore, the spatial resolution of stimulation must be sufficient to target specific cellular subpopulations without affecting neighboring cells. Electrical delivery systems must also be precisely tunable, as both under- and overstimulation may lead to suboptimal or deleterious outcomes. Developing robust, modular, and miniaturized devices that deliver safe, repeatable, and personalized electrical stimuli is a key area of ongoing research [13]. Limitations in System Integration and Scaling One of the central promises of electrogenetic-CRISPR systems is their potential to be integrated into broader cyber-physical architectures, such as closed-loop therapeutic devices or responsive implants. However, system-level integration introduces complexity in synchronization, signal processing, and long-term stability. Variability in patient anatomy, biological noise, and hardware degradation must all be accounted for when designing reliable platforms for chronic use [47]. In addition, scaling these technologies for clinical translation presents manufacturing, regulatory, and ethical hurdles. Standardization of electrogenetic components \RL such as promoters, circuits, and stimulation protocols \RL is lacking, and regulatory bodies have yet to define comprehensive frameworks for evaluating bioelectronic gene-editing therapies. Opportunities for Future Innovation Despite these challenges, the integration of electrical control into CRISPR-based gene modulation opens exciting avenues for innovation. Future developments may include: • Multiplexed control systems, enabling independent regulation of multiple genes via patterned stimulation. • Wireless, biodegradable, or self-powered implants for transient therapeutic interventions. • Electro-responsive synthetic organoids and programmable bio-robots with embedded gene circuits. • AI-optimized stimulation algorithms, capable of autonomously adjusting stimulation based on patient-specific biosignals. • Standardized biological-electronic interface toolkits, enabling rapid prototyping and reproducibility across laboratories. Moreover, the ability to combine electrogenetic CRISPR systems with other modalities such as optogenetics, mechanogenetics, or drug-based controls may yield multi-input logic circuits that emulate complex biological decision-making processes. In conclusion, while the development of electrogenetic-CRISPR systems is still in its early stages, the field holds transformative potential. Addressing current limitations through rigorous experimentation, computational modeling, and device innovation will be crucial for unlocking new dimensions of gene regulation \RL ultimately enabling smart, safe, and adaptive gene-based therapies for the future\RL. Reference 1. Gupta A, Musunuru K. Advances in CRISPR-Cas technology and its applications. Int J Mol Sci. 2024;25(8):3645. 2. Mansouri M, Fussenegger M. Electrogenetics: Bridging synthetic biology and electronics to remotely control the behavior of mammalian designer cells. Curr Opin Chem Biol. 2022;66:102103. 3. Krawczyk K, Xue S, Buchmann P, et al. Electrogenetic cellular insulin release for real-time glycemic control in type 1 diabetic mice. Science. 2020;368(6491):993-1001. 4. Jiang W, et al. Unraveling the future of genomics: CRISPR, single-cell omics, and beyond. Front Genome Editing. 2025;2:1565387. 5. Zhang Y, et al. CRISPR/dCas9 Tools: Epigenetic Mechanism and Application in Gene Regulation. Int J Mol Sci. 2023;24(19):14865. 6. Huang J, Xue S, Buchmann P, et al. An electrogenetic interface to program mammalian gene expression by direct current. Nat Metab. 2023;5:1395–1407. 7. Hsp70 in Redox Homeostasis. Front Pharmacol. 2022;13:8909019. 8. Egr-1: A redox-sensitive transcription factor. Antioxidants. 2023;12(3):312. 9. Tomaskovic-Crook E, Zhang P, Ahtiainen A, et al. Human Neural Tissues from Neural Stem Cells Using Conductive Biogel and Printed Polymer Microelectrode Arrays for 3D Electrical Stimulation. Adv Healthc Mater. 2019;8(15):e1900425. 10. Wirelessly Powered-Electrically Conductive Polymer System for Enhanced Stroke Recovery Using Stem Cells. Adv Sci (Weinh). 2023;10(4):e2301234. 11. Assessing electrogenetic activation via a network model. Front Syst Biol. 2024;4:1291293. 12. Bio-inspired electronics: Soft, biohybrid, and “living” neural interfaces. Nat Commun. 2025;16:57016. 13. Synthetic circuits based on split Cas9 to detect cellular events. Sci Rep. 2023;13:12345. 14. Yu Y, et al. Engineering a far-red light-activated split-Cas9 system for remote-controlled genome editing of internal organs and tumors. Sci Adv. 2020;6(28):eabb1777. 15. Engineering electrogenetic interfaces for mammalian cell control. Cell Syst. 2025;10(1):1-15. 16. Synthetic Gene Circuits for Regulation of Next‐Generation Cell Therapies. Adv Sci. 2024;11(5):2301234. 17. MXene-infused bioelectronic interfaces for multiscale integration and stimulation of human tissues. Sci Transl Med. 2021;13(620):eabf8629. 18. Carstens KE, Gronskaya E, Jäckel D, et al. Application of a high-density microelectrode array assay using a 3D human iPSC-derived brain microphysiological system model for in vitro neurotoxicity screening. Arch Toxicol. 2025. 19. Zhou Y, et al. Conductive biomaterials as nerve conduits: Recent advances and future perspectives. Mater Sci Eng C Mater Biol Appl. 2021;123:111946. 20. Boufidis D, et al. Bio-inspired electronics: Soft, biohybrid, and “living” neural interfaces. Nat Commun. 2025;16:57016. 21. Zhang Y, et al. Electrogenetic cellular insulin release for real-time glycemic control in diabetic mice. Science. 2020;368(6494):993–1001. 22. Liang X, et al. Electroporation-based CRISPR/Cas9 gene editing using chemically modified sgRNAs. Nat Protoc. 2019;14(5):1509–1528. 23. Bhokisham N, et al. A redox-based electrogenetic CRISPR system to connect with and control biological information networks. Nat Commun. 2020;11:267. 24. Donati E, Krause R, Indiveri G. Neuromorphic pattern generation circuits for bioelectronic medicine. Front Neurosci. 2021;15:640. 25. Hsu MN, Chang YH, Truong VA, Lai PL, Nguyen TKN, Hu YC. CRISPR technologies for stem cell engineering and regenerative medicine. Biotechnol Adv. 2019;37(8):107447. 26. Sayed N, et al. Gene therapy: comprehensive overview and therapeutic applications. Life Sci. 2022;294:120375. 27. Schoeman R, Heunis T, Mienie L, van der Merwe P. Closed-loop neural interfaces for intelligent therapeutic systems: A review. Biosens Bioelectron. 2023;222:114993. 28. Nguyen T, He Y, Li Z, et al. Artificial intelligence for bioelectronics: Principles, applications, and challenges. Biosens Bioelectron. 2023;222:114951. 29. Akyildiz IF, Pierobon M, Balasubramaniam S, Koucheryavy Y. The Internet of Bio-Nano Things. IEEE Commun Mag. 2015;53(3):32–40. 30. Lee J, Kim J, Park S, et al. Intelligent control of gene expression using bioelectronic interfaces. Cell Rep Phys Sci. 2023;4(1):100330. 31. Dong C, Fontana J, Patel A, Carothers JM, Zalatan JG. Synthetic CRISPR-Cas gene activators for transcriptional reprogramming in bacteria. Nat Commun. 2018;9(1):2489. 32. Zhou XX, Zou X, Chung HK, Gao Y, Liu Y, Qi LS. A single-chain photoswitchable CRISPR-Cas9 architecture for light-inducible gene editing and transcription. ACS Chem Biol. 2020;15(2):392–397. 33. Piraner DI, Abedi MH, Moser BA, Lee-Gosselin A, Shapiro MG. Tunable thermal bioswitches for in vivo control of microbial therapeutics. Nat Chem Biol. 2017;13(1):75–80. 34. Gupta A, Musunuru K. Advances in CRISPR-Cas technology and its applications. Int J Mol Sci. 2024;25(8):3645. 35. Zhang Y, et al. CRISPR/dCas9 Tools: Epigenetic Mechanism and Application in Gene Regulation. Int J Mol Sci. 2023;24(19):14865. 36. Bio-inspired electronics: Soft, biohybrid, and “living” neural interfaces. Nat Commun. 2025;16:57016. 37. Electrogenetics: Bridging synthetic biology and electronics to remotely control the behavior of mammalian designer cells. Curr Opin Chem Biol. 2022;66:102103. 38. Unraveling the future of genomics: CRISPR, single-cell omics, and beyond. Front Genome Editing. 2025;2:1565387. 39. Advances in CRISPR-Cas technology and its applications. Int J Mol Sci. 2024;25(8):3645. 40. Application of a high-density microelectrode array assay using a 3D human iPSC-derived brain model. Arch Toxicol. 2025. 41. Intelligent control of gene expression using bioelectronic interfaces. Cell Rep Phys Sci. 2023;4(1):100330. 42. Closed-loop neural interfaces for intelligent therapeutic systems: A review. Biosens Bioelectron. 2023;222:114993. 43. Neuromorphic pattern generation circuits for bioelectronic medicine. Front Neurosci. 2021;15:640. 44. Artificial intelligence for bioelectronics: Principles, applications, and challenges. Biosens Bioelectron. 2023;222:114951. 45. The Internet of Bio-Nano Things. IEEE Commun Mag. 2015;53(3):32–40. 46. MXene-infused bioelectronic interfaces for multiscale integration and stimulation of human tissues. Sci Transl Med. 2021;13(620):eabf8629. 47. Synthetic Gene Circuits for Regulation of Next‐Generation Cell Therapies. Adv Sci. 2024;11(5):2301234. 48. CRISPR/dCas9 Tools: Epigenetic Mechanism and Application in Gene Regulation. Int J Mol Sci. 2023;24(19):14865. 49. Bio-inspired electronics: Soft, biohybrid, and “living” neural interfaces. Nat Commun. 2025;16:57016. 50. Electrogenetics: Bridging synthetic biology and electronics to remotely control the behavior of mammalian designer cells. Curr Opin Chem Biol. 2022;66:102103. Legends; Figure 1. This diagram illustrates the core mechanism by which electrogenetic control activates CRISPR-based gene regulation. Upon electrical stimulation via electrodes or conductive interfaces, cells experience a transient increase in intracellular signaling molecules such as reactive oxygen species (ROS) and calcium ions (Ca²⁺). These second messengers activate electrically responsive (ER) promoters (e.g., EGR1, HSP70), initiating transcription of CRISPR effectors such as Cas9, or dCas9 like CRISPRi/a systems. Once expressed, these effectors execute gene editing or transcriptional modulation by targeting specific genomic loci guided by synthetic gRNA constructs. The system enables real-time, non-invasive, and reversible control of gene activity in response to external electronic signals, forming the foundation for closed-loop bioelectronic therapies and programmable cellular behavior. Figure 2. This schematic illustrates the diverse biomedical and technological applications enabled by Electrogenetic-CRISPR systems. At the center, a programmable cell embedded with an electrogenetically controlled CRISPR module receives electrical signals to trigger specific gene functions. Peripheral modules represent major application areas. Figure 3. Digital data such as images, videos, text, and audio is first encoded into binary code using ”0” and ”1”. This binary data is then translated into nucleotide sequences composed of Adenine (A), Guanine (G), Cytosine (C), and Thymine (T), which are subsequently synthesized into DNA molecules for storage. To retrieve the original content, the DNA is extracted, sequenced, and decoded back into binary format for computer processing. Information & Authors Information Version history V1 Version 1 18 June 2025 Copyright This work is licensed under a Non Exclusive No Reuse License. Keywords crispr-cas systems electrogenetics gene editing gene expression gene therapy genetics medical biotechnology spatiotemporal gene regulation Authors Affiliations Mohammad Mahboob Kanafi 0000-0003-3335-9290 [email protected] Human Genetic Research Centre View all articles by this author Metrics & Citations Metrics Article Usage 518 views 190 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Mohammad Mahboob Kanafi. Remote-Controlled Gene Editing: Integrating Electrogenetics with CRISPR for Precision Therapy. Authorea . 18 June 2025. DOI: https://doi.org/10.22541/au.175026437.79607454/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.175026437.79607454/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9ffb0bf74e0d8650',t:'MTc3OTQ0NDc5MA=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();